Clinical trials: Relapsed
Germ Cell Tumour
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
The treatment of germ cell tumours is considered to be one of the major successes in the area of cytotoxic chemotherapy. Even in patients who relapse after first line therapy, a durable remission rate of between 25% and 60% has…
- Trial name
- GAMMA (NCT01782339)
- Testing
- Combination Chemotherapy
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Barts & The London NHS Trust
Lymphoma
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or…
- Trial name
- NCT00003245
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Childhood Acute Lymphoblastic Leukemia
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia.
- Trial name
- NCT00098839
- Testing
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone
- Where
- 46 sites in United States, Australia and 2 more
- Volunteers
- 134 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the…
- Trial name
- NCT03590171
- Testing
- Bortezomib
- Where
- 15 sites in Australia, Austria and 13 more
- Volunteers
- 250 people
- Sponsor
- Charite University, Berlin, Germany
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06277011
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003395
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
Leukemia cells grow and divide fast and out of control. In normal cells, certain proteins called CDK4 and CDK6 control cell growth. The study drug called palbociclib works by blocking the CDK4 and CDK6 proteins.
- Trial name
- NCT03515200
- Testing
- Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Severe Acute Malnutrition
Mother Screening for Relapse Using Mid-upper Arm Circumference Among Children Recovered From Severe Acute Malnutrition
The investigators propose a pilot randomized controlled trial to train mothers to screen their children post-discharge for relapse based on MUAC criteria to facilitate timely identification and referral to care for children who…
- Trial name
- NCT05932992
- Testing
- Mother education on how to perform MUAC assessment
- Where
- Burkina Faso
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Lymphoma, Brain Neoplasms
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Background: The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells.
- Conditions
- Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma
- Trial name
- NCT01236586
- Testing
- RO4929097, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
- Trial name
- NCT03826992
- Testing
- Vyxeos, Venetoclax
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Lymphoma
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058292
- Testing
- filgrastim, rituximab, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Vivax Malaria
Study on the Treatment of Vivax Malaria
This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or…
- Trial name
- VHX (NCT01074905)
- Testing
- Artesunate, Chloroquine, Chloroquine/Primaquine
- Where
- Thailand
- Volunteers
- 655 people
- Sponsor
- University of Oxford
Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Relapsed/refractory acute lymphoblastic leukemia remains a challenge in the context of limited access to immunotherapy in developing countries.
- Conditions
- Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL
- Trial name
- NCT07039877
- Testing
- Venetoclax low dose with itraconazole
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
Primary Objective: To estimate the incidence of treatment-emergent and treatment-related adverse events during treatment with blinatumomab in pediatric and adolescent subjects with B-precursor ALL in second or later bone marrow…
- Trial name
- RIALTO (NCT02187354)
- Testing
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Where
- 19 sites in United States, Austria and 5 more
- Sponsor
- Amgen
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Relapse
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
The aim of this study was to compare the differences in relapse and failure rates in patients treated with fixed retainers (FRs) using Computer-Aided Design/Computer-Aided Manufacturing technology, lab-based technique, and…
- Trial name
- NCT05915273
- Testing
- Computer Aided Design/ Computer Aided Manufacturing Retainers, Lab-based Retainers, Chairside Retainers
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Nourhan M.Aly
Cancer, Relapsed Cancer
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received…
- Conditions
- Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- myCare-102 (NCT05693831)
- Testing
- Cellworks Report
- Where
- United States
- Volunteers
- 730 people
- Sponsor
- Cellworks Group Inc.
Primary Immune Thrombocytopenia (ITP)
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or…
- Trial name
- NCT05718856
- Testing
- TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00054431
- Testing
- imatinib mesylate, decitabine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.